Coherus Oncology, Inc.
Coherus Oncology, Inc.
Explore linked clinical trials.14 results ยท Page 1 of 1
Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| STC-15 as a Part of Combination Therapy With Toripalimab in Selected Advanced Cancers and as Monotherapy in Participants With Selected Sarcomas | Neoplasms by Histologic Type, Neoplasms, Adipose Tissue, Neoplasms, Connective and Soft Tissue, leiomyosarcoma, liposarcoma, myomatous neoplasm, neoplasm, sarcoma | Recruiting | Phase 1 / Phase 2 | 2026-10-07 | NCT06975293 | |
| Immunotherapy (Toripalimab) for Reducing Recurrence Risk After Surgery for Mismatch Repair Deficient Stage IIB, IIC, or III Colon Cancer | Digestive System Diseases, Digestive System Neoplasms, Neoplasms by Site, colonic disorder, colonic neoplasm, colorectal neoplasm, digestive system disorder, digestive system neoplasm, intestinal disorder, neoplasm | Recruiting | Phase 2 | 2026-10-02 | NCT07140679 | |
| PhII Study of Toripalimab Followed by Definitive CRT & Adjuvant Toripalimab in Locally Advanced ESCC | Digestive System Diseases, Digestive System Neoplasms, Esophageal Neoplasms, Head and Neck Neoplasms, Neoplasms by Histologic Type, Neoplasms by Site, carcinoma, digestive system disorder, digestive system neoplasm, epithelial neoplasm, esophageal disorder, esophageal squamous cell carcinoma, neoplasm, squamous cell carcinoma, squamous cell neoplasm | Not yet recruiting | Phase 2 | 2026-09-23 | NCT07836049 | |
| Toripalimab With Chemotherapy for Sinus Cancer | Head and Neck Neoplasms, Neoplasms by Histologic Type, Neoplasms by Site, Nose Neoplasms, Otorhinolaryngologic Neoplasms, carcinoma, epithelial neoplasm, nasal disorder, neoplasm, otorhinolaryngologic disease, paranasal sinus disorder, paranasal sinus neoplasm, respiratory system disorder, respiratory tract neoplasm, sinonasal undifferentiated carcinoma, squamous cell carcinoma, squamous cell neoplasm | Recruiting | Phase 2 | 2026-08-31 | NCT06940180 | |
| Neoadjuvant Dupilumab and Toripalimab in MSS CRC Subjects With Resectable Liver Metastases | Digestive System Diseases, Digestive System Neoplasms, Neoplasms by Site, colonic disorder, colorectal neoplasm, digestive system disorder, digestive system neoplasm, intestinal disorder, neoplasm, rectal disorder | Recruiting | Phase 1 / Phase 2 | 2026-08-12 | NCT07277322 | |
| Study of CHS-114 in Participants With Advanced Solid Tumors | Head and Neck Neoplasms, Neoplasms by Histologic Type, Neoplasms by Site, carcinoma, epithelial neoplasm, head and neck squamous cell carcinoma, neoplasm, squamous cell carcinoma | Active, not recruiting | Phase 1 | 2026-08-12 | NCT05635643 | |
| A Study of Toripalimab in Combination With Cisplatin and Gemcitabine in Participants With Recurrent Metastatic Nasopharyngeal Cancer | Head and Neck Neoplasms, Neoplasms by Site, Otorhinolaryngologic Neoplasms, Pharyngeal Diseases, Stomatognathic Diseases, nasopharyngeal disorder, nasopharyngeal neoplasm, neoplasm, otorhinolaryngologic disease | Recruiting | Phase 4 | 2026-07-30 | NCT06457503 | |
| A Trial of Casdozokitug in Combination With Toripalimab Plus Bevacizumab in Participants With Unresectable and/or Locally Advanced or Metastatic Hepatocellular Carcinoma | Digestive System Diseases, Digestive System Neoplasms, Liver Neoplasms, Neoplasms by Histologic Type, Neoplasms by Site, adenocarcinoma, carcinoma, epithelial neoplasm, hepatocellular carcinoma, liver disorder, neoplasm | Active, not recruiting | Phase 2 | 2026-07-15 | NCT06679985 | |
| A Study of CHS-114 (Tagmokitug) in Combination With Toripalimab and/or Other Treatments in Participants With Advanced Solid Tumors | Digestive System Diseases, Digestive System Neoplasms, Esophageal Neoplasms, Head and Neck Neoplasms, Neoplasm Metastasis, Neoplasms by Histologic Type, Neoplasms by Site, Neoplastic Processes, Pathologic Processes, Pathological Conditions, Signs and Symptoms, carcinoma, colonic disorder, colorectal neoplasm, digestive system disorder, digestive system neoplasm, epithelial neoplasm, esophageal adenocarcinoma, esophageal disorder, esophageal squamous cell carcinoma, gastric neoplasm, intestinal disorder, neoplasm, rectal disorder, squamous cell carcinoma, squamous cell neoplasm, stomach disorder | Recruiting | Phase 1 | 2026-07-15 | NCT06657144 | |
| PDT For Induction Therapy For Head And Neck Cancer | Head and Neck Neoplasms, Neoplasms by Histologic Type, Neoplasms by Site, carcinoma, epithelial neoplasm, head and neck cancer, head and neck squamous cell carcinoma, neoplasm, squamous cell carcinoma, squamous cell neoplasm | Recruiting | Phase 2 | 2026-07-14 | NCT07214987 | |
| Neoadjuvant Chemotherapy and Programmed Cell Death Protein 1(PD-1) Inhibition for Head and Neck Cancer Treatment De-escalation (NeoScorch HN) | DNA Virus Infections, Disease Attributes, Genital Diseases, Head and Neck Neoplasms, Infections, Mouth Neoplasms, Neoplasms by Histologic Type, Neoplasms by Site, Otorhinolaryngologic Neoplasms, Pathologic Processes, Pathological Conditions, Signs and Symptoms, Pharyngeal Diseases, Stomatognathic Diseases, Tumor Virus Infections, Urogenital Diseases, carcinoma, epithelial neoplasm, head and neck cancer, human papilloma virus infection, infectious disease, laryngeal disorder, laryngeal neoplasm, larynx cancer, mouth disorder, neoplasm, oral cavity cancer, otorhinolaryngologic disease, respiratory system disorder, respiratory tract neoplasm, sexually transmitted disease, squamous cell carcinoma, squamous cell neoplasm, viral infectious disease, viral sexually transmitted disease | Recruiting | Phase 2 | 2026-04-23 | NCT07209189 | |
| Window of Opportunity in Preserving Laryngeal Function Trial | Disease Attributes, Head and Neck Neoplasms, Neoplasm Metastasis, Neoplasms by Histologic Type, Neoplasms by Site, Neoplastic Processes, Pathologic Processes, Pathological Conditions, Signs and Symptoms, Recurrence, carcinoma, epithelial neoplasm, head and neck squamous cell carcinoma, hypopharynx squamous cell carcinoma, neoplasm, squamous cell carcinoma | Recruiting | Phase 2 | 2026-04-13 | NCT07423078 | |
| Combination Immunotherapy for the Treatment of Chemotherapy-refractory Metastatic MSS CRC | Digestive System Diseases, Digestive System Neoplasms, Neoplasms by Site, colonic disorder, colorectal neoplasm, digestive system disorder, digestive system neoplasm, intestinal disorder, neoplasm, rectal disorder | Recruiting | Phase 1 / Phase 2 | 2026-02-19 | NCT07281716 | |
| A Study of CHS-1000 in Participants With Advanced or Metastatic Solid Tumors | neoplasm | Not yet recruiting | Phase 1 | 2024-09-19 | NCT06389526 |